Why Are Aridis Pharmaceuticals Shares Moving Higher Today?
Portfolio Pulse from Vandana Singh
Aridis Pharmaceuticals Inc (NASDAQ:ARDS) shares are gaining after the company announced positive feedback from the European Medicines Agency on its proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301. The agreements by the EMA were similar to those agreed by the FDA. The company's shares are up 29.40% at $0.34 during the premarket session.
July 18, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aridis Pharmaceuticals shares are gaining after positive feedback from the EMA on its Phase 3 study of AR-301. The stock is up 29.40% in premarket trading.
The positive feedback from the EMA on Aridis Pharmaceuticals' Phase 3 study of AR-301 is a significant development for the company. This news is likely to boost investor confidence in the company's prospects, leading to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100